Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Acq. announced
Consulting agrmnt
|
|
Enliven Therapeutics, Inc. (IMRA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/01/2023 |
8-K
| Acquisition/merger/asset purchase announced, Entered into consulting agreement|
Docs:
|
"Certificate of Amendment to the Company’s Restated Certificate of Incorporation",
"Certificate of Amendment to the Company’s Restated Certificate of Incorporation",
"Contingent Value Rights Agreement between the Company and Rights Agent",
"November 10, 2022",
"February 14, 2020",
"Rahul Ballal Separation Agreement",
"March 15, 2022",
"ENLIVEN THERAPEUTICS, INC. Confirmatory Employment Letter",
"ENLIVEN THERAPEUTICS, INC. Confirmatory Employment Letter",
"Contingent Value Rights Agreement between the Company and Rights Agent" |
|
| 10/13/2022 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Agreement and Plan of Merger, by and among Imara Inc., Iguana Merger Sub, Inc. and Enliven Therapeutics, Inc",
"Form of Contingent Value Rights Agreement",
"Form of Enliven Support Agreement",
"Form of Imara Support Agreement",
"Form of Lock-Up Agreement",
"Enliven Therapeutics and Imara Announce Merger Agreement",
"Investor Presentation" |
|
|
|